Validation of ELISA methods for quantification of total tau and phosporylated-tau181 in human cerebrospinal fluid with measurement in specimens from two Alzheimer's disease studies.
暂无分享,去创建一个
E. Siemers | H. Vanderstichele | R. Dean | G. Sethuraman | R. Demattos | P. May | Martin J. Romeo | E. Coart | R. Konrad | D. Lachno | Jayne A. Talbot | Hans F Jensen | J. Zajac | R. DeMattos | D. R. Lachno
[1] Charless C. Fowlkes,et al. Alzheimer’s Disease Neuroimaging Initiative , 2005 .
[2] K. Blennow,et al. Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease , 2010, Alzheimer's & Dementia.
[3] J. Trojanowski,et al. Total and phosphorylated tau protein as biological markers of Alzheimer’s disease , 2010, Experimental Gerontology.
[4] W. M. van der Flier,et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. , 2009, JAMA.
[5] W. M. van der Flier,et al. A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease , 2009, Annals of clinical biochemistry.
[6] R. Petersen,et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.
[7] A. Fleisher,et al. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. , 2008, Archives of neurology.
[8] P. Deyn,et al. Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia , 2008, Neurobiology of Aging.
[9] E. Siemers,et al. P4-346: Safety, tolerability and biomarker effects of an Abeta monoclonal antibody administered to patients with Alzheimer's disease , 2008, Alzheimer's & Dementia.
[10] P. Lewczuk,et al. Neurochemical dementia diagnostics: State of the art and research perspectives , 2008, Proteomics.
[11] M. Verbeek,et al. Diagnostic Accuracy of ELISA and xMAP Technology for Analysis of Amyloid β42 and Tau Proteins , 2007 .
[12] M. Goedert,et al. A Century of Alzheimer's Disease , 2006, Science.
[13] Viswanath Devanarayan,et al. Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement , 2006, Pharmaceutical Research.
[14] K. Blennow,et al. CSF biomarkers for mild cognitive impairment and early Alzheimer's disease , 2005, Clinical Neurology and Neurosurgery.
[15] Anders Wallin,et al. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. , 2005, Clinical chemistry.
[16] P. Scheltens,et al. Amyloid β(1–42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease , 2004, Neurology.
[17] K. Blennow,et al. CSF markers for incipient Alzheimer's disease , 2003, The Lancet Neurology.
[18] Trey Sunderland,et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. , 2003, JAMA.
[19] L. Parnetti,et al. CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies , 2001, Neurological Sciences.
[20] K. Blennow,et al. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke , 2001, Neuroscience Letters.
[21] K. Blennow,et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization , 2000, Neuroscience Letters.
[22] K. Blennow,et al. Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample. , 1999, Neurology.
[23] Y. Nakamura,et al. Basic and clinical studies on the measurement of tau protein in cerebrospinal fluid as a biological marker for Alzheimer's disease and related disorders: multicenter study in Japan. , 1998, Methods and findings in experimental and clinical pharmacology.
[24] J. Kornhuber,et al. Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease , 1997, Neuroscience Letters.
[25] P. Cohen,et al. Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein. , 1994, The Biochemical journal.
[26] M. Vandermeeren,et al. Affinity Purification of Human τ Proteins and the Construction of a Sensitive Sandwich Enzyme‐Linked Immunosorbent Assay for Human τ Detection , 1992, Journal of neurochemistry.
[27] M. Kirschner,et al. A protein factor essential for microtubule assembly. , 1975, Proceedings of the National Academy of Sciences of the United States of America.
[28] W. M. van der Flier,et al. Variability in longitudinal cerebrospinal fluid tau and phosphorylated tau measurements , 2008, Clinical chemistry and laboratory medicine.
[29] Juan Manuel Maler,et al. Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer’s disease , 2007, Journal of Molecular Neuroscience.
[30] K. Blennow,et al. Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years. , 2007, Journal of Alzheimer's disease : JAD.
[31] K. Blennow,et al. Analytical performance and clinical utility of the INNOTEST® PHOSPHO-TAU(181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies , 2006, Clinical chemistry and laboratory medicine.
[32] P. Scheltens,et al. Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice. , 2005, Clinical chemistry.
[33] H. Braak,et al. Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.